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Abstract
Patients with biallelic truncating mutations in PALB2 have a severe form of Fanconi anae-
mia (FA-N), with a predisposition for developing embryonal-type tumours in infancy. Here
we describe two unusual patients from a single family, carrying biallelic PALB2mutations,
one truncating, c.1676_1677delAAinsG;(p.Gln559ArgfsTer2), and the second, c.2586
+1G>A; p.Thr839_Lys862del resulting in an in frame skip of exon 6 (24 amino acids). Strik-
ingly, the affected individuals did not exhibit the severe developmental defects typical of FA-
N patients and initially presented with B cell non-Hodgkin lymphoma. The expressed p.
Thr839_Lys862del mutant PALB2 protein retained the ability to interact with BRCA2, previ-
ously unreported in FA-N patients. There was also a large increased chromosomal radio-
sensitivity following irradiation in G2 and increased sensitivity to mitomycin C. Although
patient cells were unable to form Rad51 foci following exposure to either DNA damaging
agent, U2OS cells, in which the mutant PALB2 with in frame skip of exon 6 was induced, did
show recruitment of Rad51 to foci following damage. We conclude that a very mild form of
FA-N exists arising from a hypomorphic PALB2 allele.
Author Summary
PALB2 is a protein that creates a molecular bridge that promotes the recruitment of
Homologous Recombination Repair (HRR) proteins BRCA1, BRCA2 and Rad51 to sites
of DNA damage. Cells with functional loss of PALB2 show a defect in HRR and are char-
acterized by an increased number of spontaneous chromosome breaks and hypersensitiv-
ity to cross-linking agents. Typically, inherited mutations in PALB2 are associated with a
severe Fanconi Anaemia phenotype. Here we describe for the first time the effect of bialle-
lic mutations of PALB2 in which one hypomorphic allele resulted in a low level of expres-
sion of the mutant PALB2 protein with some retained function, as shown by its
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interaction with BRCA2, as well as its ability to facilitate Rad51 focus formation following
damage. This resulted in a considerably milder clinical phenotype with increased longevity
compared with biallelic PALB2 null patients and an altered tumour spectrum towards
development of lymphoid malignancies.
Introduction
BRCA2, PALB2, BRCA1, Rad51 and the Rad51 paralogs form the principal constituents of the
homologous recombination (HR) machinery utilised by the cell not only to repair deleterious
DNA lesions, such as DNA double strand breaks (DSBs) in an error-free manner, but also to
stabilise, protect and restart damaged replication forks. PALB2 [1] functions as a molecular
bridge by simultaneously binding both BRCA1 and BRCA2 via its N-terminal coiled-coil
domain and C-terminal WD repeats respectively [2–4]. It has been proposed that BRCA1 plays
a role in targeting the BRCA2-Rad51 recombination complex to sites of DNA damage directly
through its ability to bind PALB2 [3]. However, since PALB2 and Rad51 foci are not
completely ablated in the absence of BRCA1 and PALB2 has been shown to bind chromatin
directly through its ChAM domain [5], it is likely that PALB2 acts as an essential conduit link-
ing the pro-resection, anti-recombinogenic and the cell cycle checkpoint activities of the vari-
ous known BRCA1 containing complexes (typified by the presence of RAP80, MERIT40,
Abraxas, BRCC36/45, CtIP or FANCJ) with the recombination machinery [6].
It has been known for some time that heterozygosity for a germline mutation in either
BRCA1 or BRCA2 strongly predispose women to the development of breast and/or ovarian
cancer. More recently, heterozygosity for a germline mutation in PALB2 [7], RAD51C [8] and
RAD51D [9] have also been associated with an increased risk of developing breast and ovarian
cancer. These observations highlight a critical role for the HR pathway in protecting against
cellular transformation, particularly of hormone-responsive, epithelial cells that have a high
proliferative capacity. Interestingly, however, it has been shown that biallelic, null germline
mutations in BRCA2 [10–14] and PALB2 [15–17], hypomorphic mutations in BRCA1 [18,19]
and Rad51C [20], or in the case of RAD51 [21] a dominant mutation, all give rise to a spectrum
of clinical symptoms that have features of Fanconi Anaemia (FA). Unlike Fanconi anaemia
patients with mutations of one of the core complex Fanconi proteins, those with inherited
mutations in the HR machinery, including PALB2mutant patients, typically display severe
developmental abnormalities, such as microcephaly, growth retardation, intellectual
impairment as well as skeletal abnormalities. These patients also commonly exhibit kidney
malformations, microphthalmia, skin hypo/hyper-pigmentation, hypoplastic thumbs and
gonadal dysgenesis, although unlike typical FA patients, bone marrow failure is almost never
observed. Cells derived from these patients are almost invariably hyper-sensitive to DNA
cross-linking agents, e.g. mitomycin C (MMC) and diepoxybutane, as well as ionising radiation
(IR), consistent with a defect in homologous recombination. Given the clinical similarity
between FA and the consequences of mutations in HR genes, patients with biallelic mutations
in BRCA2, PALB2, BRCA1, RAD51C and the RAD51 dominant mutation have been designated
FA-D1, FA-N, FA-S, FA-O and FA-R respectively. The severity of the defects exhibited by HR-
defective patients serves to emphasise the importance of the recombination pathway in dealing
with DSBs and damaged replication forks that occur naturally with fairly high frequency dur-
ing development.
In contrast to the consequences of mono-allelic mutation of these genes in carriers, biallelic
null mutations predispose patients to embryonal tumours, e.g. Wilms’ tumour, neuroblastoma,
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medulloblastoma and AML in infancy. The different spectrum of tumours that develops in the
FA-like patients, compared with carriers heterozygous for a germline mutation, probably arises
as a consequence of inactivating HR early in embryonal cells versus inactivation in an already
differentiated cell type.
Given the rarity of patients with biallelic mutations in genes involved in the HR machinery,
the range of the clinical symptoms displayed by the affected individuals is limited. Indeed, all
hitherto described FA-N patients have two truncating PALB2mutations and a very similar,
severe clinical presentation. Here we describe a family with two PALB2mutations where the
affected individuals presented with few of the clinical features typically exhibited by FA-N
patients. Unlike FA-N individuals who present in infancy, patients in this study presented at
an older age and did not exhibit most of the developmental abnormalities associated with this
FA complementation group. Interestingly, although the affected patients developed tumours at
a relatively early age, these were B cell lymphomas rather than embryonal tumours. We dem-
onstrate that the PALB2 protein produced from one of the mutant alleles carried by these
patients retains both its N- and C-terminal domain required to interact with BRCA1 and
BRCA2 respectively. We also show that this mutant PALB2 preserves some function compared
with previously identified patient-associated mutant PALB2 proteins and allows low level
recruitment of Rad51 foci at sites of DNA damage. We propose that the presence of this
mutant protein accounts for the milder MMC hyper-sensitivity exhibited by cells from these
patients and the lack of defining clinical characteristics. Lastly, the identification of this family
implicates PALB2 as a potential suppressor of lymphoid tumourigenesis and raises the possibil-




A 12 year old girl (II-4) was admitted to hospital in August 2008 with enlarged cervical lymph
nodes and enlarged tonsils. The histopathology of the lymph node biopsy revealed B cell non
Hodgkin lymphoma, stage II. The tumour exhibited a CD20+, CD79a+, CD 10+, immunophe-
notype, Bcl-2 focal positivity, Ki-67>90% positivity, whereas other markers were negative
including CD3, CD45RO, CD15, CD30, ALK and EMA.
The patient was subsequently treated according to B NHL BFM 2004 protocol (arm R2: ele-
ment A twice—dexamethasone, VCR, ARA-C, etoposide, MTX, IFO; element B twice—dexa-
methasone, VCR, DOXO, MTX, cyclophosphamide) until November 2008 without any
episode of WHO Grade III or IV toxicity. Since then, she has entered and remained in com-
plete clinical remission. She is now aged 19 years.
Notably, the patient did not have typical features of Fanconi anemia such as radial aplasia,
aplastic anaemia or malformation of the kidneys. Renal echosonography as well as cardiac US
were normal. Rather, she showed a slight degree of learning difficulty with problematic speech
and pronunciation. However, in similarity with Fanconi anaemia height and weight were both
below the 3rd centile for age. She also had a Mongol spot at the sacral area, a pigmented nevus
at the right gluteus and dysmorphic facies. Peripheral blood cytogenetic analysis showed a nor-
mal karyotype (46, XX), although numerous spontaneous chromatid and isochromatid breaks
were observed. Serum AFP was slightly elevated (35.4 μg/L; normal range: 0–13.4 μg/L) and
immunoglobulin assay showed elevated IgM at 5.03 g/L. No mutations in the TP53 gene were
detected.
A younger sister (now aged 15 years) (II-5) was also successfully treated for non-Hodgkin
lymphoma at age 3.5 years. She had normal CBC, elevated AFP (34.4 μg/L) and normal
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immunoglobulin levels including IgM. The peripheral blood karyotype obtained from this sib-
ling was also normal. Physical examination showed height and weight both below the 3rd cen-
tile, epicanthus, café au lait spot on the left shoulder (4x2 cm) and another larger café au lait
spot (>10 cm diameter) on the left hip. Notably, this child had learning difficulty and speech
impairment.
In August 2008 the family history revealed 5 additional siblings: The oldest brother (II-1)
was aged 21 years and healthy, whereas the second brother (II-2) died at age of 3.5 years due to
a bone cancer of unknown origin. The oldest sister (aged 15 years) (II-3) and siblings II-6
(aged 6 years) and II-7 (aged 4 years) also showed learning difficulty and speech impairment
(Fig 1).
Unusual sensitivity to ionizing radiation and DNA crosslinking agents
The increased spontaneous chromosome breakage observed in blood lymphocytes from the
affected patients (II-4 and II-5) was suggestive of a possible underlying DNA repair deficiency.
To investigate this, we assessed the repair capacity of cells derived from one of the affected
patients following exposure to IR (using both G2 chromosomal breakage analysis and colony
survival assays) and also the DNA cross-linking agent MMC, (using both chromosomal break-
age analysis and colony survival assays). Lymphocytes from the affected patient exhibited a
high level of chromosome breakage, notably triradials and quadriradials, in response to MMC,
similar to the level in two of the control Fanconi patients of unknown complementation group.
Strikingly, a very high level of damage in response to IR was seen, higher than the level
observed in A-T lymphocytes, indicative of a severe DNA repair defect (Table 1).
Interestingly, in contrast to the results obtained from the chromosomal breakage analysis,
fibroblasts from both affected sisters had a normal sensitivity to IR as judged by colony survival
and an intermediate sensitivity to MMC, when compared to a fibroblast cell line derived from
a typical FA patient of unknown complementation group (although FA-A is the most com-
mon)(Fig 1). The apparent disparity between the two different IR assays can be explained by
the fact that the IR induced chromosomal breakage is a consequence of unrepaired DNA dam-
age occurring in G2-phase, whereas colony survival assays with skin fibroblasts take into
account repair across the entire cell cycle. Given that approximately 85% of all DSBs, irrespec-
tive of cell cycle phase, are repaired by NHEJ, a normal survival response to IR, increased G2
chromosomal radiosensitivity and decreased MMC survival indicated a defect in HR.
Since mutations in the Mre11-Rad50-Nbn (MRN) complex give rise to a chromosomal
hypersensitivity to both IR and MMC and, at least in the case of NBS patients predisposition to
developing lymphoid malignancies, such as B cell lymphomas, we monitored the activation of
ATM in response to DSBs using Western blotting coupled with phospho-antibodies to known
substrates of ATM. Notably, the IR-induced phosphorylation of ATM (Ser-1981) as well as
that of Smc1 (Ser-966) and Nbn (Ser-343), all of which are known to be reduced in the absence
of a functional MRN complex, were completely normal in an LCL derived from patient II-5
(Fig 2). Similar results were obtained using fibroblasts derived from both patients II-4 and II-5
(S1 Fig). Since ATM could be efficiently activated in cells from both affected patients and the
levels of Nbn were unaltered, this indicated that it was unlikely that the underlying DNA repair
defect could be accounted for by a deficiency in the MRN complex.
Abnormal IRIF focus formation
Given that our preliminary analysis of cells derived from the two affected sisters suggested an
underlying HR defect, we next determined whether cells from these patients exhibited any
problems recruiting specific DNA repair proteins to sites of DSBs or DNA cross-links. At early
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time points following exposure to a low dose of IR, fibroblasts from patients II-4 and II-5 were
able to relocalise MDC1, 53BP1, BRCA1, FANCD2 and RPA2 to sites of DSBs marked by
γH2AX foci, in a manner similar to a normal fibroblast cell line. Comparable results were
obtained when the patient cells were exposed to low dose MMC (S2 Fig). However, in keeping
Fig 1. Clinical and cellular features of affected siblings. A) Pedigree of family showing affected siblings. It is not known whether sibling II-2 also had the
same syndrome as II-4 and II-5. B) Colony forming assay following exposure of fibroblasts to 137Cs γ-rays, C) Colony forming assay following exposure of
fibroblasts to Mitomycin C. The proportion (%) of surviving colonies was plotted against dose. The assay was repeated at least three times for each cell
strain. Error bars show the s.e.m of survival at each dose.
doi:10.1371/journal.pgen.1005945.g001
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with an underlying DNA repair deficiency, both patients’ fibroblasts displayed residual foci at
late times post-irradiation (S2 Fig).
In stark contrast to our findings assessing the relocalisation of MDC1, 53BP1, BRCA1,
FANCD2 and RPA2, fibroblasts from both affected patients completely failed to recruit Rad51
to sites of DNA damage induced by either IR or MMC (Fig 3). In light of the fact that Rad51
foci formation was not completely abolished in the absence of BRCA1 and that cells from our
affected patients could still efficiently relocalise BRCA1, this suggested that the underlying
genetic defect in our unusual DNA repair deficient family most likely arose as a consequence of
mutations in PALB2, BRCA2 or RAD51.
Protein and Mutation analysis in cells from family members
Based on the inability of the affected patient cells to form Rad51 foci in response to DNA dam-
age, we utilised Western blotting to assess the levels of BRCA1, BRCA2, PALB2 and Rad51 in
cells from affected patient II-5. Whilst BRCA1 and Rad51 were readily detectable in the
affected patient tested compared to normal cells, full length PALB2 was completely absent and
the stability of BRCA2 significantly reduced (S3 Fig) presumably due to the low level of stabilis-
ing mutant PALB2 protein. Interestingly, two faint lower molecular weight bands detected
with the PALB2 antibody were present in cells from patient II-5 indicating the presence of
expressed truncated mutant protein (Fig 4A and 4B).
Following sequencing of the PALB2 gene in both sisters, we identified two deleterious muta-
tions: c.1676_1677delAAinsG; (p.Gln559ArgfsTer2) in exon 4 and c.2586+1G>A; (p.
Thr839_Lys862del), a base substitution in the first base of intron 6 that affected the donor
splice site resulting in an in frame skip of exon 6 (24 amino acids) (Fig 5A–5D). Further analy-
sis of these mutations in other family members revealed that the mother and sibling II-3 inher-
ited the c.1676_1677delAAinsG; (p.Gln559ArgfsTer2)(p.Q559RfsTer2) mutation, whereas the
father and sibling II-6 inherited the c.2586+1G>A; (p.Thr839_Lys862del)(p.T839_K862del)




















50 0 2 2 8 1 0 0 0
(2) Following exposure to 0.1μgml-1 mitomycin C for 4h and cultured to 48h Patient II-5
50 1 2 2 27 20 8 8 3
Normal control
50 0 0 0 0 0 0 0 0
Three typical Fanconi anaemia patients
50 0 0 0 22 11 4 5 0
50 0 0 0 26 21 10 10 0
50 0 0 0 16 19 0 1 0
(3) Following exposure to 1.0 Gray γ-rays@ G2 Patient II-5
50 1 3 4 81 54 29 18 9
Normal control
50 0 0 0 6 0 0 0 0
Two classical ataxia telangiectasia patients (positive control)
50 0 0 0 65 18 1 1 0
50 0 0 0 49 29 1 2 0
doi:10.1371/journal.pgen.1005945.t001
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mutation and sibling II-7 carried two normal alleles. Mutations were not detected in BRCA2 or
RAD51 in II-4 and II-5.
Consistent with the identified mutations, the high and low molecular weight proteins
detected in cells from patient II-5 with the PALB2 antibody corresponded to the approximate
sizes of the p.Thr839_Lys862del and p.Gln559ArgfsTer2 mutant PALB2 proteins respectively
(Fig 4). The smaller protein, at about 90kD, was the same size as another protein that cross-
reacted with this antibody.
Interestingly, the N-terminal coiled coil domain (aa9-44) of PALB2 that has been shown to
interact with BRCA1 [3,4] was retained in both mutant proteins. In contrast, the C-terminal
WD-40 repeat domain of PALB2 that is essential for its interaction with BRCA2 was only pre-
served in the p.Thr839_Lys862del mutant protein. It was, therefore, speculated that the mild
Fig 2. Normal ATM signaling in patient cells. ATM from the lymphoblastoid cell line of II-5 is able to
autophosphorylate (panel A), shows a normal level (panel B, lanes 5 & 6) as well as normal signalling as
indicated by phosphorylation of ATM targets Smc1Ser966 (panel C) and NbnSer343 (panel E), as is the case
for the normal control (lanes 1 & 2). Lanes 3 & 4 show the A-T control, where there is no ATM (panel B) and
no evidence of ATM signalling. Panels D & F show the total levels of Smc1 and Nbn respectively.
doi:10.1371/journal.pgen.1005945.g002
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Fig 3. Absence of Rad51 foci in fibroblasts from patients II-4 & II-5. Following exposure to either 3Gy IR
or 50ngml-1 mitomycin C no Rad51 foci were detected in fibroblasts from II-4 and II-5. γH2AX foci indicate the
presence of DNA DSB. The residual foci at 24h following IR are consistent with a DNA repair deficiency.
doi:10.1371/journal.pgen.1005945.g003
Hypomorphic PALB2Mutation and Lymphoid Tumours
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Fig 4. Analysis of expression of PALB2 protein in a family with previously unrecognised FA-N
patients. A) Western blot showing loss of full length PALB2 in the affected patient II-5 (Ab 301-246A)(lane 3).
However, there is the presence of a faint signal for a slightly smaller protein, probably corresponding to the
exon six deletion mutation. Also present in the patient lane is a much smaller band at 90kDa. Lane 4 is lysate
of cells from a FA-D1 (biallelic mutation of BRCA2) patient. B) All relatives of the patient II-5 show bands for
WT PALB2. Also found in the lanes for the mother (I-2) and sibling II-3, (lanes 3 and 7) is the smaller dense
90kD protein band consistent with I-2 and II-3 carrying the c.1676_1677delAAinsG mutation. In addition, a
Hypomorphic PALB2Mutation and Lymphoid Tumours
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clinical presentation of the disease in affected siblings, together with the absence of embryonal
tumours, could be attributed to residual function of the exon 6 deletion mutant PALB2
protein.
Functional analysis of mutant PALB2 proteins
Remarkably, the two PALB2mutations (T839_K862del and Q559RfsTer2) identified in our
atypical FA-N family were similar to two PALB2mutations (Y551Ter) and an in frame rever-
tant (Exon4delRev) with both the N- and C-terminal domains that was derived by Xia et al,
[15] from the EUFA1341 cell line. In keeping with the position of known binding sites on the
PALB2 protein, the Y551Ter mutant was unable to interact with BRCA2 and as such could not
complement the MMC hypersensitivity or Rad51 foci defect of the EUFA1341 cell line. In con-
trast, the in frame Exon4delRev PALB2 retained its ability to bind to BRCA2 and could com-
plement cellular defects exhibited by the EUFA1341 cell line [15].
In order to examine the capability of our two different patient mutant PALB2 proteins to
interact with BRCA2, isogenic Flp-In/T-Rex U2OS cells were generated that inducibly
expressed FLAG tagged WT PALB2, the individual PALB2mutations identified in our
FANCN family and the individual mutations described by Xia et al, [15]. An siRNA sequence
directed against the 3’UTR of the PALB2mRNA (not present in the exogenous PALB2 open
reading frame) was used to deplete endogenous PALB2 protein to prevent the presence of this
WT protein interfering with our interaction studies.
Following siRNA-mediated depletion of endogenous PALB2 protein, the induced FLAG-
tagged exogenous PALB2 was immunoprecipitated with an anti-FLAG antibody and the pres-
ence of BRCA2 verified by Western blotting. Consistent with previous observations by Xia
et al, [15] WT PALB2 and the revertant lacking exon 4 (Exon4delRev), but not the Y551Ter
mutant, were able to robustly co-immunoprecipitate BRCA2 (Fig 6A). In a similar fashion,
despite being expressed at low levels, the p.T839_K862del mutant PALB2 protein, but not the
C-terminally truncated mutant (Q559RfsTer2), could interact with BRCA2 (Fig 6A). Taken
together, these data are consistent with the notion that the exon 6 deleted p.T839_K862del
PALB2 mutant allele lacking the 9 most N-terminal amino acids of the WD40 repeat region
still interacts with BRCA2 and, therefore, possesses some residual activity.
We, subsequently, investigated the activity of the p.T839_K862del mutant PALB2, by carry-
ing out a complementation assay examining the localisation of Rad51 foci in the different
U2OS cell lines that expressed either FLAG-tagged WT or mutant PALB2 proteins (S4 Fig).
U2OS cells were plated on to coverslips and following siRNA-mediated depletion of endoge-
nous PALB2 protein and induction of the FLAG-tagged exogenous PALB2 the location of
Rad51 was determined. Expression of the Y551Ter (present in the EUFA1341 cell line) and the
Q559RfsTer2 PALB2 protein from our patient did not permit recruitment of Rad51 foci to the
sites of damage following MMC or IR treatment. This was in contrast to induction of the rever-
tant PALB2 lacking exon 4 (Exon4delRev), as well as the exon 6 deleted p.T839_K862del
mutant PALB2 in our patient, where recruitment of Rad51 foci following damage was seen in
both instances (Fig 7). Therefore, the exon 6 deleted p.T839_K862del mutant PALB2 can,
indeed, allow Rad51 recruitment to the sites of damage and the reason for the absence of
Rad51 foci in patient cells is related to the low level of expression of this mutant PALB2.
less dense band of the same size, 90kD, appears as a consequence of the antibody cross reacting with
another protein. This cross reacting band is visible in the normal control (both left and right), I-1, II-7 and II-6.
The father carries the c.2586+1G>A, although the exon 6 deleted protein cannot be seen against the
background of the normal full length protein from his WT allele.
doi:10.1371/journal.pgen.1005945.g004
Hypomorphic PALB2Mutation and Lymphoid Tumours
PLOS Genetics | DOI:10.1371/journal.pgen.1005945 March 18, 2016 10 / 21
Fig 5. PALB2mutations in the affected family. Electropherograms of PALB2mutations in DNA in the affected siblings. A) Top panel, c.1676_1677delAAinsG
in genomic DNA; lower panel,wt sequence at that position. B) Top panel mutant c.2586+1G>A in genomic DNA; lower panel,wt sequence at that position. C)
cDNA sequencing showing that the c.2586+1G>Amutation causes exon 6 to be omitted during RNA splicing. D) Diagramatic representation of the PALB2
protein and predicted effects of mutations. Diagram of PALB2 showing the epitopes to which the two anti-PALB2 antibodies bind and also the locations of the
mutations in the patients. Note that because the epitope for the PALB2 antibody 246A is in exon 4, the exon revertant protein (Exon4delRev) deletion mutant
Hypomorphic PALB2Mutation and Lymphoid Tumours
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cannot be detected with this antibody. Similarly, because the Y551Ter and Q559RfsTer2 mutants truncate at residues 551 and 559 respectively, they do not
possess the epitopes for the 247A antibody. Only wild type and T839_K862del exon six deletion PALB2 are detectable with both antibodies.
doi:10.1371/journal.pgen.1005945.g005
Fig 6. Co-immunoprecipitation of BRCA2 with mutant PALB2 proteins. A) Cultures of U2OS cell lines
that inducibly express FLAG-taggedWT or mutant PALB2 proteins were transfected with PALB2 siRNA and
induced to express the tagged PALB2 proteins by treatment with doxycycline. Samples were incubated with
anti-FLAG antibody and immunoprecipitates electrophoresed and blotted serially with mouse anti-BRCA2
(top panel), rabbit anti-PALB2 246A antibody (middle panel) and then rabbit anti-PALB2 247A antibody
(bottom panel). 246A antibody was not stripped before blotting with 247A. A band approximating to 460kDa
and detected with anti-BRCA2 antibody was immunoprecipitated with FLAG-taggedWT, T839_K862del
(exon 6 deleted) and PALB2 revertant (Exon4delRev) proteins, in those samples that were incubated with
anti-FLAG antibody. Anti-PALB2 antibodies identified FLAG-taggedWT protein at ~170kDa as expected
(lane 1), with the exon 6 deleted protein appearing to be slightly smaller (lane 2). The FLAG-tagged
Q559RfsTer2 and Y551Ter proteins were found at their expected sizes (middle panel). The FLAG-tagged
PALB2 revertant protein (Exon4delRev) was evident with Ab 247A in bottom panel. B) Samples of the NETN
lysates were taken as ‘input’ samples before immunoprecipitation, and 5% of total lysate immunoprecipitated
was subjected to PAGE andWestern blotting. The filters were blotted serially with different antibodies as in A.
These blots show BRCA2 in all samples before immunoprecipitation. Anti-PALB2 antibodies identify FLAG-
tagged PALB2 protein in all WT and mutant expressing cell lines. The aprataxin protein indicates the
similarity of loading.
doi:10.1371/journal.pgen.1005945.g006
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Fig 7. Recruitment of Rad51 foci to sites of damage in U2OS cells expressing FLAG-tagged exon 6 deleted p.T839_K862del mutant PALB2.
Recruitment of Rad51 foci to sites of damage in U2OS cells that expressed FLAG-taggedWT, revertant PALB2 lacking exon 4 (Exon4delRev) or exon 6
deleted T839_K862del mutant PALB2, but not in cells expressing Y551Ter (present in the EUFA1341 cell line) or the Q559RfsTer2 PALB2, following
depletion of endogenous PALB2 and MMC or IR exposure.
doi:10.1371/journal.pgen.1005945.g007
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Prediction of the effect of loss of PALB2 exon 6 on the structure of
PALB2
PALB2 contains a seven-bladed beta-propeller (WD40-repeat) at its C-terminus [22]. Blade 7
of this repeat is formed by C-terminal beta-strands 7A, 7B and 7C, which are ‘zipped’ back to
the first N-terminal strand (7D) in order to complete and seal the protein fold. A PALB2
Y1183Ter mutation, which resulted in loss of the 4 most C-terminal residues (strand 7C), is
predicted to lead to incomplete folding and instability of the mutant protein [22]. Indeed, no
truncated PALB2 protein was detected in patient cell lysates harbouring this mutation [16].
Interestingly, in the patients we describe here, amino acid residues 839–862 are deleted from
the protein, which includes the entirety of beta-strand 7D (857–862: LVSELK) (Fig 8A).
Using sequence-threading and manual modelling strategies [23, PyMOLMolecular Graphics
System, Version 1.7.4 Schrödinger, LLC] we were able to generate a model for the mutant form
of the protein, and compare this to the X-ray crystal structure of the wild-typeWD40-repeat
(PDB: 2W18). Loss of beta-strand 7D could be expected to lead to destabilisation of the protein
fold, as several hydrogen bonds between the component beta-strands that form Blade 7 would
not be made. However, this particular region of the protein is also hydrophobic in nature, and
the side-chains of beta-strand 7D also contribute to stability of the fold via van der Waals inter-
actions. In particular, the side chain of Leu861 (strand 7D) is buried in a small hydrophobic
pocket, lined by residues Asn863, Ile887, Thr889, Trp898, Trp906 and Ile1180 (Fig 8B).
Secondary structure predictions [23] indicate helical propensity for the amino acid sequence
immediately upstream of strand 7D. The in-frame deletion of exon 6, would lead to a direct
fusion of this helical region to the start of theWD40-repeat (i.e. replacing beta-strand 7D). Side
chains of Cys828, His832 and Val836 protrude from one face of the modelled helix, and can be
Fig 8. Suggested model of the mutant PALB2WD40-repeat. A) Amino acid sequence of the region immediately upstream of the PALB2WD40-repeat.
The in-frame deletion, created by the skipping of exon 6, is indicated by the black box. The position of beta-strand 7D and the upstream region of helical
propensity are indicated by the magenta arrow and yellow box respectively. The amino acids visible in the X-ray crystal structure of the wild-type PALB2
WD40-repeat (PDB: 2W18) are also indicated. B) In the wild-type protein Leu861 of beta-strand 7D sits in a small hydrophobic pocket lined by the indicated
amino acids. C) Molecular cartoons showing the N-terminal part of theWD40-repeat (cyan). (Left) the labelled amino acids (coloured asterisks), on one face
of the upstream helical element (yellow), resemble structurally and spatially, those of the 7D beta-strand (Right, magenta).
doi:10.1371/journal.pgen.1005945.g008
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positioned such that they resemble in part, structurally and spatially, those of beta-strand 7D
(Val858, Ser859 and Leu861 (Fig 8C). Moreover, Val836 is positioned to interact with the
hydrophobic pocket—normally occupied by Leu861—and hence stabilise the protein fold.
This suggests one potential way in which the fold of the mutant WD40-repeat may be
retained. A second plausible alternative, is that another, more distant part of the PALB2 pro-
tein, can adopt a similar beta-strand conformation to that of 7D, and again stabilise the fold.
Although the in-frame deletion clearly affects the overall stability of the truncated protein in
patient cells, is it nevertheless still detectable, albeit at a reduced level.
The mutant form of the protein can also be transiently expressed in U2OS cells, but again is
unstable compared with full length PALB2.
Loss of beta-strand 7D, like the Y1183Ter mutation, might be expected to affect closure of
the WD40-repeat and lead to protein mis-folding and targeted degradation. However, the
mutant protein is clearly functional, as demonstrated by its ability to interact with BRCA2 (Fig
6A) and by facilitating Rad51 recruitment to foci.
Discussion
Here we describe an unusual family in which the affected individuals have biallelic mutations
in PALB2, yet do not display the clinical features typically associated with the disease. We pro-
pose that the mild clinical phenotype exhibited by the affected patients in this family results
from the presence of an expressed mutant PALB2 protein that retains a sufficient level of WT
activity.
PALB2 functions as a molecular bridge linking BRCA1-containing DNA repair complexes
with the core HRmachinery consisting of BRCA2, Rad51 and the Rad51 paralogs. The C-termi-
nal WD40 domain of PALB2 is the major binding site for BRCA2 and as a consequence is essen-
tial for the formation of Rad51 foci in response to DNA damage. The N-terminal coiled-coil
domain of PALB2 is required for its ability to interact with BRCA1 [3,4]. However, the func-
tional relevance of this interaction is unclear. It has been reported that BRCA1 targets the
PALB2-BRCA2 complex to sites of DNA damage. Whether this occurs directly through its abil-
ity to bind PALB2, or indirectly via its role in promoting DNA end-resection, is not known.
Unlike loss of BRCA2, compromising BRCA1 expression does not completely abrogate the abil-
ity of PALB2 to relocalise to sites of DNA damage or promote Rad51 nucleofilament formation,
suggesting that this interaction may be required to increase the efficiency of HR. Despite this,
there is conflicting evidence as to whether the BRCA1-PALB2 interaction is actually required
for DNA repair or not. Simhadri et al, [24] reported that an engineered triple point mutation in
the murine PALB2 gene that reduced its ability to bind BRCA1 gave rise to a mild DNA repair
defect. In contrast Xia et al, [15] showed that a C-terminally truncated PALB2 that still retains
its BRCA1 binding site could not complement the DNA repair defects exhibited by a FA-N
patient-derived cell line. Based on these observations and the fact that we could co-precipitate
the T839_K862del but not the Q559RfsTer2 patient-associated mutant PALB2 protein with
BRCA2, we suggest that the T839_K862del mutant PALB2 allele retained sufficient function to
alleviate the clinical symptoms associated with a PALB2 deficiency. Structural modelling of this
hypomorphic patient mutation indicated that, whilst the loss of residues Thr839-Lys862 located
proximal to a small hydrophobic pocket within blade 7 of theWD40 repeat domain is likely to
destabilise the protein due to loss of several critical hydrogen bonds, repositioning of upstream
hydrophobic residues Cys828, His832 and Val836 may in part compensate for the loss of the
missing amino acids and provide some increased stability of the mutant protein (Fig 6). As a
consequence, expression of this mutant protein, albeit at reduced levels, may be sufficient to alle-
viate the clinical symptoms and cellular defects exhibited by the affected patients.
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Interestingly, cells derived from the affected patients from this family do not form Rad51
foci in response to either DNA DSBs or cross-links. In contrast, following either IR or MMC
exposure Rad51 foci were observed in U2OS cells that expressed the exon 6 deleted
T839_K862del mutant PALB2. Therefore, the T839_K862del mutant PALB2 does retain resid-
ual function, but it is not expressed at levels sufficient to result in detectable Rad51 foci in
patient cells. Rather, it appears that Rad51 is recruited to sites of DNA damage in these patient
cells at a level that is below detection by standard immunofluorescence.
The presence of the p.Thr839_Lys862del mutant PALB2 impacts on the ability of the cell to
repair DNA damage by HR as shown by the large increase in G2 chromosome damage following
IR exposure. The disparity between the IR-induced chromosomal breakage and the colony sur-
vival analysis of the affected patient cells is readily explained. The chromosomal analysis assay,
described here, predominantly measures G2 phase DSB repair, which will detect defects in both
NHEJ and HR. In contrast, the colony survival assay will primarily detect abnormalities in the
NHEJ pathway since the DNA damage is induced in an asynchronous culture in which the vast
majority of the fibroblasts will be in G1 phase of the cell cycle. Absence of increased radiosensi-
tivity by colony forming assay has been observed in FA-D1 cells [25], although a chromosome
assay of FA-D1 lymphocytes exposed at G2 showed them to be very radiosensitive. A similar
insensitivity to IR by colony forming ability, but clear increased sensitivity to chromosome dam-
age following G2 irradiation, has also been observed in both fibroblasts and lymphoblasts from
patients with Cornelia de Lange Syndrome [26] with a defect in sister chromatid cohesion.
Interestingly, our observations, which are consistent with deficient DNADSB repair as a result
of a defect in HR in these hypomorphic PALB2 patients, using the same endpoint (Table 1)
show an effect greater than seen in classical ataxia telangiectasia patients. The G2 chromosomal
radiosensitivity of our patients with hypomorphic PALB2mutations is also greater than seen in
Fanconi patients with likely mutations in the FA core complex proteins [27].
In contrast, following exposure to MMC the colony forming ability of fibroblasts from
patients II-4 and II-5, while impaired compared with normal, appeared not to be as deficient as
cells from core complex protein Fanconi patients, PALB2 patients [15,16] or FA-D1 patients
[25,26]. Published data for chromosomal sensitivity to MMC does not appear to be available
for FA-D1 or FA-N patient lymphocytes compared with core complex patients. We assume
that the chromosomal sensitivity to MMC of our hypomorphic PALB2 patient was less than
that of a null patient. While null PALB2 (and BRCA2) patients have a defect in both DNA dou-
ble strand break repair and also the resolution of DNA crosslinks leading to their profound
clinical presentation, the presence of the hypomorphic PALB2mutation alleviates this
considerably.
The clinical features of the two siblings (II-4 and II-5) shown to have the biallelic PALB2
mutations included abnormally small size, dysmorphic facies and lymphoid tumour develop-
ment. It is less clear whether the learning difficulty and speech impairment are part of the
PALB2 syndrome in this family, because of their occurrence in other family members without
biallelic mutation of PALB2. Most strikingly, these sisters did not present in infancy with the
much more severe developmental features and embryonal type tumours associated with bialle-
lic truncating mutations of PALB2 or, indeed, biallelic truncating mutation of BRCA2. How-
ever, the sisters shared the Fanconi anaemia patient characteristic of small size. The absence of
radial aplasia or abnormalities of the thumbs would not preclude a diagnosis of FA, as not all
FA patients show these features. Unlike typical Fanconi anaemia patients, however, 80% of
whom have a mutation in a core Fanconi anaemia core protein/gene, they did not have aplastic
anaemia, a common presentation of FA between ages 5–10 years. Therefore, although some
milder clinical features of FA were present, the phenotype of the affected sisters was clearly dis-
tinct from either typical PALB2 (FA-N) patients or typical FA.
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A particularly important aspect of the clinical phenotype of the patients with a PALB2 defect
described in this study is that both affected individuals developed B cell non-Hodgkin lym-
phoma (B-NHL). This tumour type clearly differs from the embryonal-type tumours that nor-
mally develop in FA-N or FA-D1 patients. The occurrence of B-NHL in this family could be
specific to the particular inherited PALB2mutation or could arise as a consequence of the
slightly older age of the affected patients in this family as compared to most classical FA-N
patients. Nevertheless, the presence of a lymphoid tumour in both affected individuals does
raise the interesting possibility that PALB2may represent a novel tumour suppressor of lym-
phoid malignancies in a manner similar to ATM and NBN.
Methods
Cell culture
Epstein-Barr virus (EBV) transformed lymphoblastoid cell lines (LCLs) were established from
the younger sister (II-5), both parents (I-1 and I-2) and siblings II-3, II-6 and II-7) (Fig 1) as
well as control lymphocytes. LCLs were cultured in RPMI 1640 medium (Sigma-Aldrich,
Irvine, UK) supplemented with 10% foetal calf serum (FCS). Fibroblast cultures were also
established from skin biopsies from both affected patients II-4 & II-5 and cells grown in
DMEM with 10%FCS.
Assays for γ-irradiation and mitomycin C sensitivity
For colony forming assays, serial dilutions of primary skin fibroblasts from a normal individ-
ual, the two affected individuals (II-4 & II-5) in the family under investigation and TERT
immortalised fibroblasts from an ataxia telangiectasia patient were irradiated with 1 to 5Gy of
γ rays. Patient, normal control and Fanconi Anaemia fibroblasts were exposed for 1h to mito-
mycin C at concentrations of 0.05–0.40μgml-1. Treated fibroblasts were seeded on to a lethally
irradiated (35Gy) feeder layer of normal fibroblasts (6x104 cells per 9.0cm dish) in DMEM
(Sigma Aldrich) with 10% FCS. Cells were plated in quadruplicate and incubated in 5% CO2 at
37°C for 18–21 days with medium changing. The medium was removed, colonies fixed with
formaldehyde and stained with 0.5% Methylene Blue (Fisher Scientific, Loughborough, UK).
The number of colonies on each plate was counted and percentage survival calculated.
To assess chromosomal radiosensitivity, whole blood cultures in RPMI 1640 + FCS were
stimulated with PHA for 72h and exposed to 1Gy 137Cs γ-rays 4h before harvesting. Colcemid
was added 1h prior to harvesting. Chromosome spreads were made using standard methods and
chromosome damage analysed by light microscopy. For chromosomal sensitivity to MMC,
whole blood cultures were exposed to either 0.01 or 0.05μgml-1 for 30 minutes, washed out and
cells harvested 48h later, again with colcemid added 1h prior to harvesting.
Immunofluorescence
Cells seeded on to coverslips were permeabilized in CSK100 buffer (10 mM PIPES, 20 mM
NaCl, 3 mMMgCl2, 300 mM sucrose, 0.5% Triton X-100) for 5 min at 4°C and then fixed in
3.6% PFA/PBS for 10 min at 4°C. Coverslips were blocked for 1h in 10% FCS in PBS, incubated
for 1h at room temperature with the primary antibody diluted in 2% FCS, washed three times
in PBS, and then incubated for an additional 1h with the secondary antibody. Coverslips were
washed again three times in PBS and then mounted onto a microscope slide with Vectashield
containing DAPI (Vector Laboratories, Burlingame, CA). Primary antibodies used were anti-
γH2AX (05–636; Merck Millipore), anti-Rad51 (PC130; Calbiochem), anti-BRCA1 (sc-6954;
Santa Cruz Biotechnology), anti-MDC1 (made by G. Stewart), anti-53BP1 (NB100-904; Novus
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Biologicals), and anti-FANCD2 (sc-20022; Santa Cruz) and anti-RPA2 (NA18; Calbiochem).
All secondary antibodies were either Alexa Fluor 488 or Alexa Fluor 594 coupled and pur-
chased from Invitrogen (Carlsbad, CA). Fluorescence images were taken using a Nikon E600
Eclipse microscope 333 equipped with a 60X oil lens, and images were acquired and analysed
using Volocity Software 334 v4.1 (Improvision).
DNA sequence analysis
DNA sequencing was performed on PCR products using the Applied Biosystems BigDye Ter-
minator v3.1 Cycle Sequencing Kit (Part No. 4336917). Sequence analysis of purified products
of sequencing reactions was performed using an Applied Biosystems 3500xL Genetic Analyzer.
PALB2 sequence variations were designated according to the reference genomic
(NG_007406.1), mRNA (NM_024675.3) and protein (NP_078951.2) sequences.
Immunoblotting for PALB2 expression and ATM kinase activity assays
To analyse the level of PALB2 expression in LCLs, cell pellets were resuspended in UTB buffer
(8M urea, 50mM Tris pH 7.5, 150mM β-mercaptoethanol) and lysed on ice by sonication.
50μg of lysate was separated by SDS-polyacrylamide gel electrophoresis and the proteins trans-
ferred to nitrocellulose membrane (Pierce). Nitrocellulose strips were subjected to immuno-
blotting and protein bands visualised using the enhanced chemiluminescence (ECL) system
and exposure to Hyper-film (GE Healthcare). PALB2 antibodies used for immunoblotting
were rabbit polyclonals A301-246A (Bethyl Laboratories) that recognises an epitope between
residues 200–250 of PALB2 and A301-247A that recognises an epitope between residues 675–
725 (see Fig 5). Other antibodies used were anti-BRCA2 (OP95; Calbiochem), anti-BRCA1
(OP92; Calbiochem), anti-Rad51 (SC-8349; Santa Cruz), anti-Aprataxin (made in house) and
anti-FLAG (F1804; Sigma-Aldrich).
To analyse ATM signalling cells were either mock-irradiated or exposed to 5Gy ionising
radiation and harvested after 30 minutes. Antibodies used for immunoblotting were: ATM
11G12 (made in house), anti-phospho ATM (S1981) (AF1655; R&D Systems), anti-SMC1
(A300-055A; Bethyl Laboratories), anti-phospho SMC1 (S966) (A300-050A; Bethyl), anti-
KAP-1 (A300-274A; Bethyl), anti-phospho KAP-1 (S824) (A300-767A; Bethyl), anti-NBN
(ab23996; Abcam), anti-phospho NBN (S343) (ab47272; Abcam), anti-phospho CHK2 (T68)
(2661; Cell Signaling Technology, New England Biolabs), anti-CREB (48H2; Cell Signaling),
anti-phospho CREB (S121) (NB100-410; Novus Biologicals), anti-γH2AX (05–636; Merck
Millipore), anti-H2A (07–146; Merck Millipore), anti-phospho BRCA1 (S1423) (Bethyl), anti-
BRCA1 (OP92; Calbiochem), anti-Chk2 (gift from Dr S. Elledge), anti-53BP1 (NB100-904;
Novus Biologicals) and anti-phospho 53BP1 (S1778) (2675; Cell Signaling Technology).
Creation of stable Flp-In/T-Rex U2OS cell lines
Isogenic U2OS cell lines inducibly expressing either WT or mutant FLAG-tagged PALB2 were
created using the Flp-In/T-Rex system. WT PALB2, or a series of PALB2 mutants were cloned
into the pcDNA5/FRT/TO plasmid containing an N-terminal FLAG tag and then transfected
into U2OS cells containing a single FRT recombination site. Transfected cells were selected
with hygromycin and blasticidin and then cloned. Expression of the inducible FLAG-tagged
PALB2 protein in each of the cell clones was determined by Western blotting. The PALB2
mutants generated in this study were a revertant PALB2 exon 4 deletion (Exon4delRev) and a
FA-N patient-derived mutation Y551Ter, both previously described by Xia et al (15) and both
exon 6 deletion (p.T839_K862del) (c. 2586+1G>A; p.Thr839_Lys862del) and Q559RfsTer2
(c.1676_1677delAAinsG; p.Gln559ArgfsTer2) identified in our patients.
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Knockdown of endogenous PALB2 using siRNA
A PALB2 siRNA (GGAGAAUAUCUGAAUGACAdTdT) directed against the 3’ UTR region
of PALB2 mRNA [4] was used to knockdown endogenous PALB2. Cells were transfected with
siRNA using Lipofectamine RNAiMAX Reagent (Invitrogen) according to the manufacturers
protocol. Four hours post-transfection 1μg/ml doxycycline was added to the cells to induce
exogenous PALB2 protein expression. The PALB2 cDNA sequences cloned in the pcDNA5--
FLAG/FRT/TO vector did not contain 3’-UTR sequences and transcripts from these constructs
were not targeted by the siRNA. Cells were harvested 48h post-transfection. The efficiency of
PALB2 knockdown was determined by Western blotting.
Immunoprecipitation
Immunoprecipitations were performed using a protocol published previously [28].
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